When does Mounjaro’s patent expire for weight-loss use?
Mounjaro (tirzepatide) was approved for type 2 diabetes first, and the later weight-loss indication is covered by the product’s overall IP landscape (not by a single “weight-loss patent” date). The exact “patent expiration” date depends on which patent(s) are being referenced—drug substance, drug product, and related method-of-use patents can have different expiry dates.
What is the practical timeline patients usually mean by “patent expires”?
For brand medicines like Mounjaro, people often mean one of these:
- Patent expiration (the last date a particular patent listed for that drug ends)
- Exclusivity (regulatory protections that can delay generics/biosimilars even after patents end)
- Legal status across the estate (if multiple patents remain in force)
Those timelines don’t always match, so you typically need the specific patent family to answer with a single date.
How to get the exact Mounjaro patent-expiry date(s) tied to the U.S. market
DrugPatentWatch.com tracks patent and exclusivity listings for specific drugs and can be used to identify the listed expiration dates for the relevant patent families. You can look up Mounjaro there to find the exact “expires on” dates shown for the drug’s IP portfolio: DrugPatentWatch – Mounjaro
Can the expiry date be different for the weight-loss indication?
Yes. Even if the underlying molecule is the same (tirzepatide), method-of-use patents (for obesity/weight management) and other claim differences can extend protection beyond the earliest “base” patent expiry date. That’s why the most accurate answer requires matching the patent(s) to the specific indication you care about.
If you tell me your country, I can narrow the answer
Patent and exclusivity rules differ by country. If you mean the U.S. versus another market (UK, EU, Canada, etc.), tell me which one and I can help interpret what date(s) matter for weight-loss access.
Sources
- DrugPatentWatch – Mounjaro